<?xml version="1.0" encoding="UTF-8"?>
<p>The 5.4% rate of toxic deaths reported here with the RiBVD regimen is in line with that observed for other first-line regimens used in older MCL patients. For instance, in a phase III study comparing the R-CHOP regimen to VR-CAP, Robak and colleagues reported 14/242 deaths (6%) and 11/240 deaths (5%), in the R-CHOP and VR-CAP arms, respectively.
 <sup>
  <xref rid="b7-1040138" ref-type="bibr">7</xref>
 </sup> Of these deaths, a total of six were due to infection and three to cardiac failure.
</p>
